About: Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.02 (+66.67%)
NX1 ASX Nexalis Therapeutics Ltd
Nexalis Therapeutics Ltd share price
NX1 price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
NX1 price performance
NX1 Market Signals